AdultPediatricDosage Forms & Strengths tablet 200mg 400mg Asthma/Reversible Bronchospasm Up to 15 mg/kg PO q6hr PRN Reduce in renal impairment Renal Impairment CrCl >50 mL/min: Administer 75% of normal dose CrCl 10-50 mL/min: Administer 50% of normal dose CrCl < 10 mL/min: Administer 25% of normal dose Hepatic Impairment Not studiedSafety & efficacy not establishedInteraction CheckerEnter a drug name and dyphyllineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (1)levoketoconazolelevoketoconazole will increase the level or effect of dyphylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.Monitor Closely (1)hydrocortisonehydrocortisone will decrease the level or effect of dyphylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Minor (0)hydrocortisoneMonitor Closely (1)hydrocortisone will decrease the level or effect of dyphylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.levoketoconazoleSerious - Use Alternative (1)levoketoconazole will increase the level or effect of dyphylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Frequency Not Defined Mild & infrequent Headache Nausea Circulatory failure Irritability Ventricular arrhythmia Hypotension Tachycardia Hyperglycemia Muscle twitching Albuminuria Diuresis Hematuria Tachypnea Restlessness Seizure Palpitation Extrasystoles Insomnia Upset stomach Contraindications Hypersensitivity to dyphylline or other xanthines Cautions Use caution in severe cardiac disease, HTN, hyperthyroidism, acute myocardial injury, peptic ulcer disease, renal impairment Not for status asthmaticus Pregnancy Category: C Lactation: Excreted in breast milk; use with cautionPregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available. Mechanism of Action Bronchodilator; also exhibits peripheral vasodilatory and bronchial smooth muscle relaxant activity Pharmacokinetics Peak plasma time: 45 min Peak plasma:concentration: 1 g dose: 17 mcg/mL Half-Life: 2 hr Absorption: Rapid Metabolism: not metabolized Excretion: Urine (88%) No images available for this drug. No images available for this drug.A Patient Handout is not currently available for this monograph.Print